‘Groundbreaking’ Type 1 Diabetes Drug Has Just Been Trialed on First Human Patients–With No Side Effects
Page 1 of 1
‘Groundbreaking’ Type 1 Diabetes Drug Has Just Been Trialed on First Human Patients–With No Side Effects
A ground-breaking clinical trial of a new investigational drug has been launched to help prevent and manage Type 1 diabetes, and researchers have already dosed the first patient in the world with the treatment.
The drug, which was developed by scientists Clinical Research Facility (CRF) at Cardiff and Vale University Health Board (UHB), aims to help the regrowth of insulin making ‘beta’ cells of the pancreas, which are lost in patients living with the disease. Despite being an early phase trial, the CRF has now dosed two patients with this new drug.
Type 1 diabetes is a serious, lifelong condition where blood glucose levels are too high because the body cannot make a hormone called insulin. Those with Type 1 diabetes are dependent on insulin but if this clinical trial works, the regrowth – or regeneration – of beta cells may mean those with Type 1 diabetes becoming far less dependent on insulin injections. The benefits of the new drug would reduce lifelong conditions and complications associated with the chronic disease.
Patients who have taken part in the trial so far have spoken very highly of the treatment and the overall experience they have received at Cardiff and Vale UHB. The first patient to receive the dose said; “I’m really grateful that I was given the opportunity to take part in this study. I hope that my participation will help with the management of Type 1 diabetes for future generations.”
After being monitored for 72 hours after the treatment, the two patients showed no side effects. Cardiff’s CRF team are hoping to attract up to eight more adult volunteers to take part in the clinical trial who have had diabetes for more than two years.
The results of this innovative trial in diabetes treatment could be ground-breaking and is part of a wider program of studies to preserve and regrow the insulin making cells in Type 1 diabetes being pursued by the Cardiff team, with trials in both adults and children.
Carys Thomas, interim Director of Health and Care Research Wales, said: “The CRF in Cardiff is not only leading the way in this ground-breaking study but the team’s hard work also shows that Wales is competing successfully on an international level to attract global pharmaceutical companies and commercial investment. It will also pave the way to bring more high quality research into Wales, which could help treat other conditions.”
(Source: Cardiff and Vale University Health Board)
https://www.goodnewsnetwork.org/groundbreaking-type-1-diabetes-drug-has-just-been-trialed-on-first-human-patients-with-no-side-effects/
The drug, which was developed by scientists Clinical Research Facility (CRF) at Cardiff and Vale University Health Board (UHB), aims to help the regrowth of insulin making ‘beta’ cells of the pancreas, which are lost in patients living with the disease. Despite being an early phase trial, the CRF has now dosed two patients with this new drug.
Type 1 diabetes is a serious, lifelong condition where blood glucose levels are too high because the body cannot make a hormone called insulin. Those with Type 1 diabetes are dependent on insulin but if this clinical trial works, the regrowth – or regeneration – of beta cells may mean those with Type 1 diabetes becoming far less dependent on insulin injections. The benefits of the new drug would reduce lifelong conditions and complications associated with the chronic disease.
Patients who have taken part in the trial so far have spoken very highly of the treatment and the overall experience they have received at Cardiff and Vale UHB. The first patient to receive the dose said; “I’m really grateful that I was given the opportunity to take part in this study. I hope that my participation will help with the management of Type 1 diabetes for future generations.”
After being monitored for 72 hours after the treatment, the two patients showed no side effects. Cardiff’s CRF team are hoping to attract up to eight more adult volunteers to take part in the clinical trial who have had diabetes for more than two years.
The results of this innovative trial in diabetes treatment could be ground-breaking and is part of a wider program of studies to preserve and regrow the insulin making cells in Type 1 diabetes being pursued by the Cardiff team, with trials in both adults and children.
Carys Thomas, interim Director of Health and Care Research Wales, said: “The CRF in Cardiff is not only leading the way in this ground-breaking study but the team’s hard work also shows that Wales is competing successfully on an international level to attract global pharmaceutical companies and commercial investment. It will also pave the way to bring more high quality research into Wales, which could help treat other conditions.”
(Source: Cardiff and Vale University Health Board)
https://www.goodnewsnetwork.org/groundbreaking-type-1-diabetes-drug-has-just-been-trialed-on-first-human-patients-with-no-side-effects/
Guest- Guest
Similar topics
» A Team Cured Diabetes in Mice Without Side Effects
» Immunotherapy Succeeds in Thwarting Type 1 Diabetes
» Did Scientists Just Develop A Viable Cure For Type 1 Diabetes?
» Eating less than 1,000 calories a day for up to five months can CURE Type 2 diabetes
» BCG vaccine can reverse Type 1 diabetes to almost undetectable levels, eight-year study shows
» Immunotherapy Succeeds in Thwarting Type 1 Diabetes
» Did Scientists Just Develop A Viable Cure For Type 1 Diabetes?
» Eating less than 1,000 calories a day for up to five months can CURE Type 2 diabetes
» BCG vaccine can reverse Type 1 diabetes to almost undetectable levels, eight-year study shows
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill